Created on:
On June 23rd, we organized the first LUMC Global Community Meeting on establishing successful Sino-Dutch collaborations in (bio)medical research and education.
With broad presence of LUMC professors, researchers, educational staff and researchers from the science faculty of Leiden University, and diplomatic staff of the Dutch Embassy and Consulates in China, we discussed current developments in research & education, R&D, funding opportunities and research ethics in China.
Nico Sciettekatte shared information about the Sino-Dutch (Suzhou) Science and Technology Innovation Park, a park that offers ample opportunity for international collaboration in China. Read more here: https://www.eusinobc.com/sino-dutch-suzhou-science-and-technology-innovation-park/
Annemarie Montulet revealed what it means that China is one of our university’s strategic focus countries, what support is offered and how to approach the topic of knowledge safety in relation to international collaborations. Did you know about this checklist for collaboration with Chinese knowledge institutes?
Furthermore, Yun Tian, Baoxu Pang and Peter ten Dijke proved to be great sources of knowledge and support for anyone taking their first steps in either finding a Chinese PhD or establishing broader institutional collaborations.
Want to learn more about some of the interesting subjects discussed in the meeting? Contact us via global@lumc.nl.
The African-European Tuberculosis Consortium (AE-TBC) is an international multisite group of African and European researchers who investigate the use of host biosignatures for the diagnosis of active TB disease. For over ten years, the LUMC groups of Infectious Diseases and Cell & Chemical Biology from Prof Annemieke Geluk and Dr Paul Corstjens respectively, have been partners of the EDCTP consortia for tuberculosis (among which AE-TBC). The AE-TBC recently won the prize for ‘Outstanding Research Team 2020, awarded by the EDCTP.
The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.
“This is an achievement in alignment with the mission of VODAN-Africa to generate continuous, real-time, high velocity clinical observational patient data from resource-limited communities that have not been well represented in digital health data. The key feature is that the data produced remains in the health facility only. It will not leave the health facility. Since the data is machine-actionable the input of the data only happens once; in the deployable architecture, the data is used for four parallel use cases” (VODAN to Africa, 2022).
© LUMC Global. All rights reserved. Website door philogirl